At least 2 months of breastfeeding may cut the risk of sudden infant death syndrome (SIDS) by half, with the protective benefit increasing as the duration increases and achieved regardless of breastfeeding patterns, a study has found.
Paediatric patients with obsessive-compulsive disorder (OCD) who respond to initial cognitive behavioural therapy (CBT) experience durable and long-term benefits of the treatment, a recent study shows.
In preschoolers with attention-deficit hyperactivity disorder (ADHD), negative parenting techniques, such as physical intrusions, appear to increase respiratory sinus arrhythmia and pre-ejection period, a new study shows. This suggests that improvements in parent-child interactions affect autonomic responses in this population.
With more than a 50-percent incidence rate, acute kidney injury (AKI) poses a serious problem to extremely low birthweight (ELBW) infants in that it cuts survival and is associated with the risk of patent ductus arteriosus, a recent study has found.
The paediatric dosing of intravenous zanamivir has a safety profile that is consistent with that expected in a population of children hospitalized for severe or progressive influenza, with majority achieving clinical improvement during the treatment course, according to a study.
While electrocardiogram (EKG) provides an earlier and more accurate neonatal heart rate than a pulse oximeter, there is not enough evidence to conclude that clinical interventions can be initiated significantly earlier, a recent study shows.
Virtual reality (VR) seems to be more effective than standard of care (SOC) in reducing pain and anxiety in children undergoing a routine blood draw, a recent randomized controlled trial (RCT) has shown.
Current tobacco smoke exposure (TSE) is not related to airflow obstruction in school-aged children, a study suggests. On the other hand, an association exists between prenatal TSE and airflow obstruction in asthmatic children.
New drug applications approved by US FDA as of 16 - 30 April 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.